Onyx Pharmaceuticals Announces December 2009 Investor Events

American Society of Hematology (ASH) Briefing and Analyst Briefing


EMERYVILLE, Calif., Nov. 25  /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that the company will host two investor events in December:

  ASH Briefing
  December 7, 2009 - 9:00 a.m. CT/10:00 a.m. ET


Principal investigators will discuss data presentations surrounding carfilzomib in relapsed and/or refractory multiple myeloma, as featured at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA.  The teleconference will begin at 9:00 a.m. CT/10:00 a.m. ET on December 7, 2009.  The live webcast will be available at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-413-3362 and using the passcode 25914947.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 25914947 later in the day.  The replay will be available on the Onyx website through January 7, 2010.

  Analyst Briefing on Development Program
  December 17, 2009 - 8:30 a.m. ET


Onyx management will host an overview of its development program on December 17, 2009 at 8:30 a.m. ET.  The program will feature presentations on multiple tumor types by external clinical investigators and members of management.  Subsequent to the prepared remarks, the company will conduct a Q&A session with panelists and members of the management team.  Further details regarding Analyst Day, including webcast information, will be announced closer to the event.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801 is a targeted alpha-folate inhibitor currently in Phase 1 testing. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com/.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals. 

DATASOURCE: Onyx Pharmaceuticals, Inc.



CONTACT:  Alex Santos of Onyx Pharmaceuticals, Inc., [phone]



Web Site:  http://www.onyx-pharm.com/ 

Copyright